SUMMARY OF BASIC LEASE PROVISIONSLease • April 6th, 2020 • Repare Therapeutics Inc. • Pharmaceutical preparations
CIG III TECHNOPARC NOMINEE INC., a company duly incorporated according to law and herein represented by ______________ duly authorized;
RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT by and between REPARE THERAPEUTICS, INC. and ONO PHARMACEUTICAL CO., LTD. January 31, 2019Research Services, License and Collaboration Agreement • April 6th, 2020 • Repare Therapeutics Inc. • Pharmaceutical preparations • New York
THIS RESEARCH SERVICES, LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), is made and entered into as of January 31, 2019 (the “Effective Date”) by and between Repare Therapeutics, Inc., a corporation organized and existing under the laws of Canada and having its principal place of business at 7210 Frederick-Banting, St-Laurent, Quebec, H4S 2A1, Canada (“Repare”), and Ono Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan and having an address of 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan (“Ono”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • April 6th, 2020 • Repare Therapeutics Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”), made as of July 9th, 2018, and effective as of the Effective Date (as hereinafter defined) is by and between:
ASSIGNMENT OF LEASE AGREEMENT ENTERED INTO IN MONTREAL, THIS 7th DAY OF June 2017Assignment of Lease Agreement • April 6th, 2020 • Repare Therapeutics Inc. • Pharmaceutical preparations
REPARE THERAPEUTICS INC. AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT September 3, 2019Registration Rights Agreement • April 6th, 2020 • Repare Therapeutics Inc. • Pharmaceutical preparations • Ontario
Each of the Persons listed on Schedule A (the “Class A Investors”) and Schedule B (the “Class B Investors”) and any Person who becomes a party pursuant to Section 7.7 (collectively, the “Investors” and individually, an “Investor”)
